TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03967756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic polyp detection system
Description: When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
Study: NCT00599170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV
Study: NCT03713216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldebain
Description: 150 mg Nalbuphine sebacate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine
Study: NCT02685995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VectorFlow TDC
Description: TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palindrome TDC
Description: TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
Study: NCT03625141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
Study: NCT04237818

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 2 bottle (30 mL) per day for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chenopodium Formosanum and Fagopyrum Esculentum Extract drink
Description: consume 2 bottle (30 mL) per day for 56 days
Study: NCT00703469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX1106-02
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose
Study: NCT03169049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency Stimulation
Description: high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Stimulation
Description: Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study: NCT01736631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Description: The CBT intervention will follow the model of social phobia by Clark \& Wells (Clark \& Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
Study: NCT02928926

Intervention type: OTHER
Intervention: intravenous thrombolysis
Description: patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons

Intervention type: OTHER
Intervention: intravenous thrombolysis
Description: patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
Study: NCT03513250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine-n-butylbromide
Description: one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
Study: NCT01312324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant docetaxel/cisplatin
Description: 3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
Study: NCT01667029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02780310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study: NCT02735603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablet.
Study: NCT01854593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: vitrectomy of 25 gauge system.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vitrectomy
Description: vitrectomy of 25 gauge system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection one day before vitrectomy
Study: NCT01147406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N6022
Description: This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
Study: NCT04564716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: vaccine for intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study: NCT03400072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised APA program
Description: Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
Study: NCT03307538

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: 15 fractions of 3-4,5 Gy (risk-adapted)
Study: NCT02897115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Description: ASAS recommended NSAID doses to treat axial spondyloarthritis.
Study: NCT02982629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letter Intervention
Description: Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder letter Intervention
Description: Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
Study: NCT03420742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets.
Study: NCT02000401

Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac Tromethamine
Study: NCT02831218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QCA and Aspirin
Description: QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QCA and Clopidogrel
Description: QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging guided and Aspirin
Description: BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging guided and Clopidogrel
Description: BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
Study: NCT02745886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin 0.85 twice daily for 6 months

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calorie restriction
Study: NCT03508414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent therapeutical fasting
Description: Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
Study: NCT02229539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxepin hydrochloride oral solution
Description: 2.5 mL (25 mg) doxepin and 2.5 mL water administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DLA (diphenhydramine, lidocaine and antacids) rinse
Description: 5.0 mL administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mL placebo and 2.5 mL water administered orally
Study: NCT02804230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Ablation - Functional
Description: MR-Guided Focused Ultrasound
Study: NCT04198636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01011
Description: LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva 120 MG in 1.7 ML Injection
Description: Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Study: NCT01194336

Intervention type: DRUG
Intervention: Huperzine A
Description: dosage form: tablet dose frequency: once only

Intervention type: DRUG
Intervention: Huperzine A
Description: dosage form: tablet dose frequency: once only

Intervention type: DRUG
Intervention: Donepezil
Description: dosage form: tablet dosage frequency: once only

Intervention type: DRUG
Intervention: Donepezil
Description: dosage form: tablet dosage frequency: once only

Intervention type: DRUG
Intervention: Galantamine
Description: dosage form: tablet dosage frequency: once only

Intervention type: DRUG
Intervention: Galantamine
Description: dosage form: tablet dosage frequency: once only

Intervention type: OTHER
Intervention: Placebo
Description: dosage form: tablet dosage frequency: once only
Study: NCT03989622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: evaluation of the visual field on the ground
Description: evaluation of the visual field on the ground
Study: NCT03631264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
Study: NCT01765582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
Study: NCT00999232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
Study: NCT03220178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
Study: NCT01765582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
Study: NCT03220178

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg per use-after first application, again at wk2, then once per month

Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant
Description: 500mg per use-after first application, again at wk2, then once per month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg per day

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: 1mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2,5mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: 2,5mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Exemestane
Description: 25mg/day
Study: NCT03674684

Intervention type: OTHER
Intervention: hydroxyethyl starch
Description: After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids

Intervention type: OTHER
Intervention: hydroxyethyl starch
Description: After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids

Intervention type: OTHER
Intervention: hydroxyethyl starch
Description: After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
Study: NCT01416272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraSoft IC Soft Contact Lenses
Description: Lenses will be worn between 8 and 16 hrs each day, for 12 months
Study: NCT01964430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
Study: NCT02571075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
Study: NCT01306903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECC
Description: Minimized extracorporeal circulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MOPS
Description: Modified and optimized perfusion system Frankfurt
Study: NCT06353477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPs® 7630
Description: EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
Study: NCT01057537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polypill
Description: The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual cardiovascular medications
Description: Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Study: NCT02572375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine Phosphate/Guaifenesin ER Tablet
Description: Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
Study: NCT04138394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
Study: NCT02572375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Phosphate/Guaifenesin IR Tablet
Description: Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
Study: NCT02044679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study: NCT01306903

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Super MOPS
Description: Super modified and optimized perfusion system Frankfurt